A Study of MD-120 in Patients With Depression

Summary

The purpose of this study is to verify the efficacy and evaluate the safety of 8-week once-daily oral administration of MD-120 in Japanese patients with depression.

Timeline

Start

2020-05-18

Primary completion

2022-07-21

Completion

2022-09-14

Outcome

Missed primary endpoint

registry analysis (superiority test); Placebo vs MD-120 50 mg; p = 0.509; LS mean difference -0.6 (95% CI -2.5 to 1.2) NCT04345471 ↗

registry analysis (superiority test); Placebo vs MD-120 100 mg; p = 0.131; LS mean difference -1.4 (95% CI -3.3 to 0.4) NCT04345471 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Desvenlafaxine	Other / unclassified	50 mg	Oral
Subject	Desvenlafaxine	Other / unclassified	100 mg	Oral

Indications